Emma Ciafaloni, MD
Vascular Neurology · Rochester, NYNPI 1578590436
Payments from drug & device makers
Across 1,246 payments — averaging $2455.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$2.7M
- Biogen$199K
- AstraZeneca$31K
- Argenx US, Inc.$30K
- UCB, Inc.$15K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$12K
- plus $78K from 21 others
Across 9 payments — averaging $2861.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$11K
- Biogen$9K
- Sarepta Therapeutics, Inc.$3K
- Novartis Pharma AG$2K
- Novartis$961
What the payments were for
- Consulting fees$382,28667%
- Speaking & faculty fees$128,54923%
- Travel & lodging$49,6519%
- Food & beverage$8,1491%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 978 | $2,695,065 |
| Biogen | 137 | $198,921 |
| AstraZeneca | 22 | $30,566 |
| Argenx US, Inc. | 23 | $29,656 |
| UCB, Inc. | 9 | $14,863 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 17 | $12,428 |
| Genentech USA, Inc. | 8 | $8,320 |
| Janssen Scientific Affairs, LLC | 8 | $7,414 |
| Novartis | 2 | $6,865 |
| PTC Therapeutics, Inc. | 2 | $5,600 |
| Pfizer | 4 | $5,180 |
| Catalyst Pharmaceuticals, Inc. | 13 | $5,143 |
| F. Hoffmann-la Roche AG | 3 | $5,005 |
| Xeris Pharmaceuticals, Inc. | 1 | $4,800 |
| Amgen | 4 | $4,314 |
| ITF Therapeutics LLC | 3 | $3,600 |
| Sanofi | 1 | $3,006 |
| UCB SA | 1 | $2,880 |
| Johnson & Johnson | 1 | $2,725 |
| Amicus Therapeutics, Inc. | 1 | $2,330 |
| Merck | 1 | $2,060 |
| Janssen Research & Development, LLC | 1 | $2,000 |
| Mesoblast, Inc. | 1 | $2,000 |
| Janssen Global Services, LLC | 2 | $1,980 |
| NS Pharma, Inc. | 1 | $1,395 |
| Boehringer Ingelheim International GmbH | 1 | $990 |
| Boehringer Ingelheim | 1 | $660 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,059,765 in reported general payments places this provider in the 95th percentile of 74 vascular neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate Hcl | 12 | $275 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Rochester
- Charles ThorntonRochester$700K
- Takamasa HigashimoriRochester$54K
- Curtis BeneschRochester$25K
- Alrabi TawilRochester$9K
- Steven GoldmanRochester$3K
- Robert GrossRochester$404
- Michael StantonRochester$373
- Bijal MehtaBuffalo$1.4M
- Koto IshidaNew York$105K
- Colum AmoryNew York$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.